Truist Financial Maintains Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
Truist Financial Keeps Their Hold Rating on Amedisys (AMED)
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
TD Cowen Sticks to Its Hold Rating for Amedisys (AMED)
Amedisys Price Target Maintained With a $101.00/Share by Deutsche Bank
Deutsche Bank Downgrades Amedisys to Hold, Maintains Price Target to $101
Amedisys Analyst Ratings
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Deutsche Bank Downgrades Amedisys to Hold From Buy, Price Target Is $101
TD Cowen Initiates Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
Amedisys: Hold Rating Affirmed Amidst Modest EBITDA Adjustments and Acquisition Offer
Amedisys Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Amedisys (AMED) Gets a Hold From TD Cowen
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Amedisys (AMED) and Draegerwerk AG & Co. KGaA (GB:0K5E)
Jefferies Upgrades UnitedHealth to Buy, Cites Growth Outlook